Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Beijing Biostar Pharmaceuticals Co Gross Margin %?
Beijing Biostar Pharmaceuticals CoHKSE:02563 9 Gross Margin % is 91.57% as of Dec. 2025, which is 15% above its 10-year median of 79.60. GuruFocus rates HKSE:02563 with a GF Score™ of 9/100. The stock has 4 warning signs investors should review. Among 734 Biotechnology companies, Beijing Biostar Pharmaceuticals Co ranks better than 87.74% on this metric.
Beijing Biostar Pharmaceuticals Co (HKSE:02563) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Beijing Biostar Pharmaceuticals Co had a gross margin of 91.57% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Beijing Biostar Pharmaceuticals Co Gross Margin % Related Terms
Beijing Biostar Pharmaceuticals Co Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Biostar Pharmaceuticals Co Gross Margin % Chart
Beijing Biostar Pharmaceuticals Co Annual Data
Trend
Dec22
Dec23
Dec24
Dec25
Gross Margin %
72.76
70.27
86.44
92.19
Beijing Biostar Pharmaceuticals Co Semi-Annual Data
HKSE:02563 vs VRTX, REGN, RVMD: Gross Margin % Comparison
For the Biotechnology subindustry, Beijing Biostar Pharmaceuticals Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Biostar Pharmaceuticals Co Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Beijing Biostar Pharmaceuticals Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Beijing Biostar Pharmaceuticals Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Beijing Biostar Pharmaceuticals Co (HKSE:02563) has a Gross Margin % of 91.57% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Beijing Biostar Pharmaceuticals Co and its competitors. This is 15% above median its historical median of 79.60. Over the past decade, Beijing Biostar Pharmaceuticals Co's Gross Margin % has ranged from 70.27 to 92.19. According to the industry distribution chart, Beijing Biostar Pharmaceuticals Co ranks #90 out of 734 companies in the Biotechnology industry, placing it in the top 12.3%.
Is Beijing Biostar Pharmaceuticals Co's Gross Margin % too high?
Beijing Biostar Pharmaceuticals Co's current Gross Margin % of 91.57% is 15% above median its 10-year median of 79.60. Over the past 10 years, this metric has ranged from a low of 70.27 to a high of 92.19. The Biotechnology industry median Gross Margin % is 60.91. Beijing Biostar Pharmaceuticals Co's value of 91.57% is 50.3% above this industry median. Based on the distribution chart, Beijing Biostar Pharmaceuticals Co ranks #90 out of 734 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Beijing Biostar Pharmaceuticals Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Beijing Biostar Pharmaceuticals Co's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Beijing Biostar Pharmaceuticals Co ranks #90 out of 734 companies for Gross Margin %. This places Beijing Biostar Pharmaceuticals Co in the top 12% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.91. Beijing Biostar Pharmaceuticals Co's value of 91.57% is 50.3% above this benchmark. Historically, Beijing Biostar Pharmaceuticals Co's own Gross Margin % has ranged from 70.27 to 92.19 over the past decade. While the company's 10-year median is 79.60 vs. the industry median of 60.91, Beijing Biostar Pharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beijing Biostar Pharmaceuticals Co's current Gross Margin % of 91.57% is 50.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Beijing Biostar Pharmaceuticals Co and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beijing Biostar Pharmaceuticals Co's current Gross Margin % is 91.57%, which is 15% above median its own 10-year median of 79.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Biostar Pharmaceuticals Co stock overvalued right now?
Beijing Biostar Pharmaceuticals Co (HKSE:02563) has a current Gross Margin % of 91.57%. The current Gross Margin % is 91.57%, which is 15% above median its 10-year median of 79.60 and 50.3% above the Biotechnology industry median of 60.91. Beijing Biostar Pharmaceuticals Co's overall GF Score™ is 9/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Beijing Biostar Pharmaceuticals Co (HKSE:02563), the current Gross Margin % is 91.57% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Beijing Biostar Pharmaceuticals Co Ltd is a synthetic biology-driven biopharmaceutical company committed to developing drugs in oncology. It has developed three core technology platforms that focus on the R&D of microbial metabolite new drugs. Its Core Product and 16 out of 19 product candidates are based on a single active pharmaceutical ingredient, namely, Utidelone, which was represented in three formulations of its product portfolio. The company's current clinical trials and programs of the Core Product and product candidates cover indications of advanced breast cancer, advanced non-small cell lung cancer, neoadjuvant for breast cancer, gastric cancer, esophageal cancer, breast cancer brain metastasis, lung cancer brain metastasis, glioblastoma, and other solid tumors.
9GF Score
Get the complete analysis for HKSE:02563
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02563 has been successfully added to your 
